WEST HAVEN, CONNECTICUT - October 24th, 2011 - NanoViricides, Inc.(OTC BB: NNVC) (the "Company")
announced today that information about its novel, proprietary anti-virus platform technology has been published in the book Bionanotechnology II: Global Prospects . The chapter entitled "Nanoviricides - A Novel Approach to Antiviral Therapeutics" provides an in-depth
presentation of the NanoViricides platform technology, evidence for how nanoviricides are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as HIV and the ocular disease, epidemic keratoconjunctivitis (EKC).
The chapter introduces the novel NanoViricides nanotechnology that possesses potent antiviral efficacy by targeting the mechanisms by which viruses attach or bind to cells. A nanoviricideŽ is believed to act like a decoy of a human cell. When
the virus sees the appropriate cell binding mimic displayed on a nanoviricide, the virus binds to it. The Company believes that the flexible nanoviricide enables cooperative binding of the nanoviricide to additional sites on the virus surface in a velcro-like
effect. This maximization of virus binding would lead to the nanoviricide spreading onto the virus particle, fusing with the virus surface, and then engulfing the virus. In the process, the coat proteins that the virus uses for binding to cells would be
expected to become unavailable. This highly targeted attack would lead to the loss of the viral coat proteins and the nanoviricide may further dismantle the engulfed virus capsid. The loss of virus particle integrity would neutralize the virus, making the virus non-infectious.
The publisher of the book, CRC Press, states "The impact and importance of nanotechnology continues to grow, and nanomedicine and biotechnology have become areas of increased development. Bionanotechnology II: Global Prospects,
David Reisner Editor, a follow-up to the editor's highly successful first volume, contains 26 entirely new contributions that provide a broad survey of research shaping this critical field. With coverage of technical and non-technical areas, the book
reports on a wide variety of activity from around the world. It discusses the role of nanotechnology in novel medical devices, bioanalytical technologies, and nanobiomaterials".
About NanoViricides : NanoViricides, Inc. ( www.nanoviricides.com ) is a
development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of
drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against
a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the
eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. This press release contains
orward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ
materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release,
and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases,
beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance
or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even
if new information becomes available in the future. Important factors that could cause actual results to differ materially from
the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors"
and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and
other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the
following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
Amanda Schuon, 310-550-7200
Reproduced with permission - "NanoViricides, Inc. "